SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Motwani, J. G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Motwani, J. G
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension

Joseph G Motwani

The Southwest Cardiothoracic Centre, Derriford Hospital, Plymouth, UK, joseph.motwani{at}phnt.swest.nhs.uk

The rationale for using angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs) in combination with thiazide diuretic therapy has centred formerly around antihypertensive synergy and counter-balancing adverse metabolic effects, particularly on potassium homeostasis. However, two recent landmark clinical trials that included high-risk hypertensive patients have now provided an evidence base for this form of combination therapy by demonstrating the efficacy of perindopril/indapamide and losartan/ hydrochlorothiazide in reducing vascular morbidity and mortality, a proportion of the benefit being unaccounted for by blood pressure reduction alone. Several unresolved issues remain concerning class effects versus specific drug effects, optimal dosing, potential differences in efficacy between ACE-I and ARBs, whether elderly mild hypertensives benefit from this form of combination therapy, and the possibility that the optimal regimen may be a triple combination of ACE-I, ARB and thiazide diuretic. These issues will be resolved by ongoing and future major endpoint trials in hypertension.

Key Words: hypertension • ACE inhibition • angiotensin receptor antagonism • thiazide diuretic • combination therapy

References

  • Cushman D., Cheung H., Sabo E., Ondetti M. Design of potent, competitive inhibitors of angiotensin-converting enzyme carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 1977;16:5484-91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B. ACE inhibition in heart failure: prospects and limitations. Cardiovasc Drugs Ther 1997;11:285-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dahlof B., Devereux RB, Kjeldsen SE et al. for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood- pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hansson L., Zanchetti A., Carruthers SG et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Opie LH Principles of combination therapy for hypertension: what we learn from the HOT and other studies - a personal point of view. Cardiovasc Drugs Ther 1998;12:425-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Carretero OA, Oparil S. Essential hypertension Part I: Definition and etiology. Circulation 2000;101:329-35.[Free Full Text]
  • Carretero OA, Oparil S. Essential hypertension Part II: Treatment. Circulation 2000;101:446-53.[Free Full Text]
  • Weinberg MS, Weinberg AJ, Zappe DH Effectively target-ting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. JRAAS 2000;1:217-33.[Medline] [Order article via Infotrieve]
  • Motwani JG, Fenwick MK, Morton JJ, Struthers AD Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure. Circulation 1992;86:439-45.[Abstract/Free Full Text]
  • Opie LH Angiotensin-Converting Enzyme Inhibitors: The Advance Continues. Third Edition, University of Cape Town Press, 1999: Ch. 3, pp 64-7; Ch. 10, pp 222-4.
  • MacGregor GA, Markandu ND, Banks RA et al. Captopril in essential hypertension: contrasting effects of adding hydrochlorothiazide or propranolol. BMJ 1982;284:693-6.[Abstract/Free Full Text]
  • Vidt DG A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension. J Hypertens 1984;2:227-33.
  • Sassano P., Chatellier G., Billaud E. et al. Comparison of increase in the enalapril dose and addition of hydrochlorothiazide as second step treatment of hypertensive patients not controlled by enalapril alone. J Cardiovasc Pharmacol 1989;13:314-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Philipp T., Letzel H., Arens H-J. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens 1997;11(suppl 2):S67-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pool JL, Cushman WC, Saini RK et al. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertens 1997;10:117-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Veterans Administration Co-operative Study Group on Antihypertensive Agents. Captopril evaluation of low doses, twice-daily doses and the addition of diuretic for the treatment of mild to moderate hypertension. Clin Sci 1982;14:127-31.
  • Pool JL, Gennari J., Goldstein R. et al. Controlled multicentre study of antihypertensive effects of lisinopril, hydrochlorothiazide and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension.J Cardiovasc Pharmacol 1987;9:S36-42.[Web of Science][Medline] [Order article via Infotrieve]
  • Scholze J. For the East Germany Collaborative Trial Group. Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. J Hypertens 1993;11:217-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chrysant SG the Lisinopril-Hydrochlorothiazide Group. Anti-hypertensive effectiveness of low-dose hydrochlorothiazide combination.A large multicenter study.Arch Intern Med 1994;154:737-43.[Abstract/Free Full Text]
  • Antonios TF, Cappuccio FP, Markandu ND et al.A diuretic is more effective than a beta blocker in hypertensive patients not controlled on amlodipine and lisinopril. Hypertension 1996;27:1325-8.[Abstract/Free Full Text]
  • Morgan T., Anderson A. Clinical efficacy of perindopril in hypertension. Pharmacol Physiol 1992;19:61-5.
  • Motwani JG, Struthers AD Interactive effects of indomethacin, angiotensin II and frusemide on renal haemodynamics and natriuresis in man. Br J Clin Pharmacol 1994;37: 355-61.[Web of Science][Medline] [Order article via Infotrieve]
  • Hansson L., Lindholm LH, Ekbom T. et al. Randomised trial of old and new antihypertension drugs in elderly patients: cardiovascular mortality and morbidity of the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Neal B., MacMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Triallists' Collaboration. Lancet 2000;356:1955-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. NEnglJMed 2000;342:145-53.[Abstract/Free Full Text]
  • Lewis EJ, Hunsicker LG, Clarke WR et al. for the Collaborative Study Group. Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
  • Brenner BM, Cooper Me, DeZeeuw D. et al. for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
  • Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.NEnglJMed 1998;338:645-52.[Abstract/Free Full Text]
  • Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lindholm LH, Ibsen H., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dahlof B., Lindholm LH, Hansson L. et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension).Lancet 1991;338:1281-5. 33. Burnier M., Brunner HR Angiotensin II receptor antagonists.Lancet 2000;355:637-45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mann J., Julius S. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998;7:176-83.[CrossRef][Medline] [Order article via Infotrieve]
  • Ramsay LE, Williams B., Johnston GD et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999;319:630-5.[Free Full Text]
  • Pfeffer MA, Demanski M., Rosenberg Y. et al. Prevention of events with ACE inhibitor (the PEACE study design). Am J Cardiol 1998;82:25H-30H.[Web of Science][Medline] [Order article via Infotrieve]
  • Gomma AH, Fox KM, on behalf of the EUROPA Investigators. The EUROPA Trial: design, baseline demography and status of substudies. Cardiovasc Drugs Ther 2001;15:169-79.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yusuf S. ONTARGET. Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial. Study design presented at the 4th International Symposium on Angiotensin II Antagonism, London UK,April 2001. (available at www.ontarget.cardio.on.ca).
  • MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.[Abstract/Free Full Text]
  • SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program.JAMA 1991;265:3255-64.[Abstract/Free Full Text]
  • Staessen JA, Fagard R., Thijs L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kilander L., Nyman H., Andren B. et al. Hypertension and associated metabolic disturbances are related to cognitive impairment. A 20-year follow-up of 999 men. Hypertension 1998;31:780-6.[Abstract/Free Full Text]
  • Barnes NM, Champaneria S., Costall B., Kelly ME, Murphy DA, Naylor RJ Cognitive enhancing actions of DUP 753 detected in a mouse habituation paradigm. Neuroreport 1990;1:239-42.[Medline] [Order article via Infotrieve]
  • Hansson L., Lithell H., Skoog I. et al. Study on Cognition and Prognosis in the Elderly (SCOPE). Blood Pressure 1999;8:177-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fogari R., Mugellini A., Zoppi A. et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in Type 2 diabetic patients. Am J Hypertens 2002;15:316-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fogari R., Zoppi A., Lazzari P. et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998;32:616-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Davis BR, Cutler JA, Gordon DJ et al. Rationale and design for the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996;9:342-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 2, 72-78 (2002)
DOI: 10.3317/jraas.2002.021
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ther Adv Cardiovasc DisHome page
F. Elijovich and C. Laffer
A role for single-pill triple therapy in hypertension
Therapeutic Advances in Cardiovascular Disease, June 1, 2009; 3(3): 231 - 240.
[Abstract] [PDF]

Home page
 Eur Heart J SupplHome page
S. Julius
Bringing VALUE to LIFE
Eur. Heart J. Suppl., April 1, 2003; 5(suppl_C): C5 - C8.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Motwani, J. G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Motwani, J. G
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement